Related Experiment Video
Updated: Jan 11, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
870
Repository Corticotropin Therapy for Refractory Noninfectious Inflammatory Ocular Diseases.
Christian Nieves-Ríos1, Ricardo A Murati Calderon1, Armando L Oliver1
1Department of Ophthalmology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA.
Journal of Clinical Medicine
|November 13, 2025
Summary
Repository corticotropin injection (RCI) effectively treated refractory noninfectious ocular inflammatory diseases in patients unresponsive to corticosteroids. RCI achieved disease inactivity in 90% of patients, offering a promising alternative treatment option.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Refractory noninfectious ocular inflammatory diseases pose significant challenges in management.
- Corticosteroids are a common treatment but can lead to severe side effects and treatment failure.
Purpose of the Study:
- To evaluate the efficacy and safety of repository corticotropin injection (RCI) in patients with noninfectious ocular inflammatory diseases refractory to corticosteroid therapy.
Main Methods:
- Retrospective cohort study including 10 patients (19 eyes) with refractory ocular inflammation.
- Repository corticotropin injection (RCI) was administered after failure of corticosteroid treatment.
- Outcomes assessed included intraocular inflammatory activity, intraocular pressure (IOP), and complications.
Main Results:
- Repository corticotropin injection (RCI) led to disease inactivity in 90% of patients, with no systemic corticosteroid use at the last visit.
- Mean IOP was significantly lower at one and four months under RCI compared to prior corticosteroid treatment.
- Posterior subcapsular cataracts were the most common complication; a 40% risk reduction in cystoid macular edema was observed.
Conclusions:
- Repository corticotropin injection (RCI) demonstrates potential as an effective alternative treatment for refractory noninfectious ocular inflammatory diseases.
- RCI may offer a favorable safety profile regarding intraocular pressure compared to corticosteroids.
- Further research is warranted to confirm these findings and explore long-term outcomes.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420
01:27Open Angle Glaucoma: Treatment
940
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
940
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473